Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants

Launched by JIANGSU PROVINCE CENTERS FOR DISEASE CONTROL AND PREVENTION · Sep 18, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at the safety and effectiveness of a vaccine that protects against several serious illnesses, including whooping cough, diphtheria, tetanus, Hib infection, and polio, in healthy infants who are 2 months old. The researchers want to see how long the vaccine works in the body and if any children get pertussis (whooping cough) between 19 and 36 months of age after receiving the vaccine.

To be part of this study, children must have already received four doses of the vaccine and their caregivers need to give consent by signing a form. However, children with certain health issues, such as bleeding disorders or other serious medical conditions, cannot participate. If eligible, participants will be monitored over the next few years to gather important information about the vaccine's long-term effectiveness and safety. This study is currently recruiting participants, and it’s a great opportunity for families to contribute to important research that could help protect children’s health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - (1)Received 4 doses of DTaP-IPV/Hib pentavalent vaccines (2) Obtained consent from the participant's caregiver and sign an informed consent form
• Exclusion Criteria:
• • -(1) Diagnosed by a physician with a coagulation abnormality (e.g., coagulation factor deficiency, coagulopathy, platelet abnormality) (2) Any other factor considered to make participation in the trial unsuitable.